Coronary disease & ACS

Optical Coherence Tomography–Guided or Intravascular Ultrasound–Guided Percutaneous Coronary Intervention: The OCTIVUS Randomized Clinical Trial

CirculationPublished Randomised controlled trial

Primary resultResult — go to the resultAbsolute difference −0.6 percentage points one-sided 97.5% CI upper boundary 0.97

Authors' conclusion

In patients with significant coronary artery lesions, OCT-guided PCI was noninferior to IVUS-guided PCI with respect to the incidence of a composite of death from cardiac causes, target vessel-related myocardial infarction, or ischemia-driven target-vessel revascularization at 1 year.

Study context

Population
Patients with significant coronary artery lesions undergoing percutaneous coronary intervention (PCI)
Participants
2,008 patients
Comparison
Optical coherence tomography (OCT)-guided vs intravascular ultrasound (IVUS)-guided PCI
  • OCTn = 1,005
  • IVUSn = 1,003reference
Primary endpoint
Composite of:
  • Cardiac death
  • Target vessel-related MI
  • Ischemia-driven target-vessel revascularization
Follow-up
1 year
Methodological detailsprospective, multicentre, open-label, pragmatic, non-inferiority
  • Prospective
  • Multicentre
  • Open-label
  • Pragmatic
  • Non-inferiority

Primary result

As reported in the abstract

Absolute difference

−0.6 percentage points

one-sided 97.5% CI upper boundary 0.97

P < 0.001 for non-inferiority

Events by treatment group

Safety

Contrast-induced nephropathy · similar

P = 0.85

Major procedural complications · lower with OCT

P = 0.047

Major procedural complications

Imaging procedure-related complications not observed

Original publication

Optical Coherence Tomography–Guided or Intravascular Ultrasound–Guided Percutaneous Coronary Intervention: The OCTIVUS Randomized Clinical Trial. Circulation. Published 27 August 2023. doi:10.1161/circulationaha.123.066429

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.